tiprankstipranks
BioMarin Pharmaceutical (DE:BM8)
FRANKFURT:BM8
Germany Market
BM8
BioMarin Pharmaceutical
RESEARCH TOOLSreports

BioMarin Pharmaceutical (BM8) Stock News & Sentiment

1 Followers
BioMarin-Backed ENERGY 2 Trial Targets High-Value Niche in Ultra-Rare Infant Disease
Premium
Company Announcements
BioMarin-Backed ENERGY 2 Trial Targets High-Value Niche in Ultra-Rare Infant Disease
19d ago
BMRN
Buy Rating on BioMarin: Strong Early Voxzogo Data, Real‑World Durability, and Underpenetrated Achondroplasia Opportunity Drive Upside
Premium
Ratings
Buy Rating on BioMarin: Strong Early Voxzogo Data, Real‑World Durability, and Underpenetrated Achondroplasia Opportunity Drive Upside
21d ago
BMRN
BioMarin Halts VOXZOGO Dosing in Select Phase 2 Trials
Premium
Company Announcements
BioMarin Halts VOXZOGO Dosing in Select Phase 2 Trials
21d ago
8K
BMRN
BioMarin: Strategic Amicus Acquisition Supports Buy Rating Despite Voxzogo Assumption Reset
Premium
Ratings
BioMarin: Strategic Amicus Acquisition Supports Buy Rating Despite Voxzogo Assumption Reset
26d ago
BMRN
BioMarin Earnings Call Highlights Growth, Pipeline, Deals
Premium
Company Announcements
BioMarin Earnings Call Highlights Growth, Pipeline, Deals
1M ago
BMRN
BioMarin: Strong Q4 Beat, Solid Multi‑Year Outlook, and Strategic Amicus Acquisition Support Buy Rating
Premium
Ratings
BioMarin: Strong Q4 Beat, Solid Multi‑Year Outlook, and Strategic Amicus Acquisition Support Buy Rating
1M ago
BMRN
BioMarin: Competitive Voxzogo Headwinds Offset by Pipeline Upside and Undervalued Long‑Term Growth Potential
Premium
Ratings
BioMarin: Competitive Voxzogo Headwinds Offset by Pipeline Upside and Undervalued Long‑Term Growth Potential
1M ago
BMRN
More DE:BM8 News >

BM8 News on the Web

BioMarin (BMRN) Down 13.6% Since Last Earnings Report: Can It Rebound?
Zacks
Neutral
How CNBC Cures is bringing rare disease stories to a national audience
CNBC
Neutral
BioMarin-Backed ENERGY 2 Trial Targets High-Value Niche in Ultra-Rare Infant Disease
TipRanks News
Bullish
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), BioMarin Pharmaceutical (BMRN) and Ionis Pharmaceuticals (IONS)
TipRanks News
Bullish
Buy Rating on BioMarin: Strong Early Voxzogo Data, Real‑World Durability, and Underpenetrated Achondroplasia Opportunity Drive Upside
TipRanks News
Neutral
Wells Fargo says buy BioMarin shares amid Phase 2 trial discontinuation weakness
TipRanks News
Bearish
BioMarin (BMRN) Halts Phase 2 Trials for Voxzogo Amid Safety Concerns
GuruFocus News
Bearish
BioMarin Halts VOXZOGO Dosing in Select Phase 2 Trials
TipRanks News
Bullish

News Score - Last 7 Days

Not enough data to generate a sentiment score
Media Buzz
This Week0 articles
Weekly Average0 articles
News Sentiment
Currently, no data available
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is DE:BM8’s Media Buzz Sentiment?
Currently, no data Available
What is DE:BM8’s weekly average amount of articles?
Currently, no data Available
What is DE:BM8’s News Sentiment?
Currently, no data Available
Healthcare Stocks that are Trending in the News
OMEROmeros
VCELVericel
AGIOAgios Pharma
2273Gushengtang Holdings Limited
ANGOAngioDynamics
Showing the stocks with the most bullish news sentiment over the past week